Skip to ContentSkip to Navigation
breed in kennis  -  sterk in techniek
Over ons Praktische zaken Waar vindt u ons dr. M. Nijland

Publicaties

Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patients

Impact of Rituximab Maintenance on Survival in Patients with Mantle Cell Lymphoma; a Population-based Cohort Study

Real-World Outcomes of High Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Multiple Myeloma Older and Younger Than 65 Years

Safety and efficacy of currently used drug therapies for treatment of lymphomas in patients with Sjögren's disease, a scoping review

Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOP

Consolidation With Second High Dose Therapy and Autologous Stem Cell Transplantation Is Associated With Improved Overall Survival in Patients With Multiple Myeloma in First Relapse

Fixed-duration epcoritamab plus R2drives favorable outcomes in relapsed or refractory follicular lymphoma

Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma

MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis

Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics

Pers/media

La consolidation de l’atezolizumab impressionne dans le DLBCL à haut risque

Atezolizumab Consolidation Impresses in High-Risk DLBCL

Rituximab Biosimilars Versus Originator: Comparing Long-Term Survival Benefit in DLBCL

Medtalks:Diffuus Grootcellig B-cellymfoom 2018

Sustainable Development Goals

SDG 3 – Goede gezondheid en welzijnSDG 9 – Industrie, innovatie en infrastructuur

Meer informatie over de Sustainable Development Goals.